Advances in immunotherapy for neuroendocrine neoplasms.
10.3760/cma.j.cn.441530-20210627-00247
- VernacularTitle:神经内分泌肿瘤免疫治疗研究进展
- Author:
Pan Pan ZHANG
1
;
Ming LU
1
;
Lin SHEN
1
Author Information
1. Department of Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Publication Type:Journal Article
- Keywords:
Anti-angiogenic drugs;
Biomarker;
Immunotherapy;
Neuroendocrine neoplasm
- MeSH:
B7-H1 Antigen;
Biomarkers, Tumor;
Humans;
Immunotherapy;
Microsatellite Instability;
Neoplasms;
Neuroendocrine Tumors/therapy*
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(10):861-866
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine neoplasms (NEN) is a rare and heterogeneous tumor. Different pathologic morphology, differentiation, grade and clinical stages of the tumors had various treatment and prognosis. Patients with recurrent or metastatic NEN have limited treatment options and poor prognosis. In recent years, PD-1 pathway blockade has become integral components of disease management for many cancers. Immunotherapy is being explored in NEN. Studies have shown that the efficacy of immune monotherapy in NEN is limited, and it can be considered for selected patients. Biomarkers for predicting efficacy of immunotherapy include PD-L1 expression, TMB-H, MSI-H/dMMR, etc. Combined regimens of anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors, and immune checkpoint inhibitor combined with anti-angiogenic drugs or chemotherapy are promising in patients with NEN, and it is worthwhile to further explore of the responding populations.
